In fact, the eventual progress of the development of a PEGylated (either 5kDa or any other polymeric moiety) amylin or an amylinomimetic compound as a pharmaceutical agent would deserve further pharmacological evaluation under a varying of dissimilar schemes, such as its use with fast acting, regular or slow-acting insulin analogues and the evaluation in animal models of T1DM and T2DM. This evidence concerns the gene IAPP and type 1 diabetes mellitus.